

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A
(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material under §240.14a-12

PRESTIGE BRANDS HOLDINGS, INC.

(Name of Registrant as Specified In Its Charter)

GENOMMA LAB INTERNACIONAL, S.A.B. DE C. V.

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
 - (1) Title of each class of securities to which transaction applies:

 - (2) Aggregate number of securities to which transaction applies:

 - (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 - (4) Proposed maximum aggregate value of transaction:

 - (5) Total fee paid:

- Fee paid previously with preliminary materials.
- Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
 - (1) Amount Previously Paid:

 - (2) Form, Schedule or Registration Statement No.:

 - (3) Filing Party:

 - (4) Date Filed:

Forward-looking Statements

This communication may contain certain forward-looking statements and information relating to Genomma Lab Internacional, S.A.B. de C.V. ("Genomma") that reflect the current views and/or expectations of Genomma and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. These risks and uncertainties include, but are not limited to, the possibility that Genomma will not pursue a transaction with Prestige Brands Holdings, Inc. ("Prestige"), the timing to consummate a potential transaction between Genomma and Prestige, the ability and timing to obtain required regulatory approvals, Genomma's ability to realize the synergies contemplated by a potential transaction and Genomma's ability to promptly and effectively integrate the businesses of Prestige and Genomma. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this communication and in oral statements made by authorized officers of Genomma. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak

On May 10, 2012, Genomma Lab Internacional, S.A.B. de C.V. delivered the following letter to Prestige Brands Holdings, Inc. :



BY EMAIL AND HAND DELIVERY

May 10, 2012

Prestige Brands Holdings, Inc.
90 North Broadway
Irvington, New York 10533
Attention: Secretary of Prestige Brands Holdings, Inc.

Re: Withdrawal of Stockholder Notice of Nomination of Persons for Election as Directors and Proposal of Stockholder Business at the 2012 Annual Meeting of Stockholders of Prestige Brands Holdings, Inc.

Dear Secretary:

Reference is made to the letter dated March 15, 2012 to the Secretary of Prestige Brands Holdings, Inc. (“Prestige”) from Rodrigo Alonso Herrera Aspra, Chairman of the Board of Directors and Chief Executive Officer of Genomma Lab Internacional, S.A.B. de C.V. (“Genomma Lab”) (the “March 15, 2012 Letter”).

Genomma Lab hereby provides notice of its withdrawal of the March 15, 2012 Letter providing notice of: (i) Genomma Lab’s nomination of five directors named therein for election to the Prestige Board of Directors (the “Board”); and (ii) Genomma Lab’s proposal to repeal any new by-laws or amendments to the Amended and Restated By-Laws, as amended of Prestige (the “By-Laws”) adopted by the Board, without stockholder approval, after September 2, 2009.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

Antonio Dovalé Jaime No. 70, Torre B, Piso 2, Colonia Santa Fe, C.P. 01210, Delegación Álvaro Obregón, México, D.F.

Sincerely,

/s/ Oscar Villalobos Torres
Oscar Villalobos Torres

Chief Financial Officer

cc: Matthew M. Mannelly, President and CEO
Daniel Wolf, Esq., Kirkland & Ellis LLP
Michael L. Fitzgerald, Esq., Dewey & LeBoeuf LLP
Samuel C. Cowley, General Counsel
